#United States #New York #CAR T-cell Therapy #Kyverna Therapeutics #KYV-101

Kyverna Therapeutics to Present at Jefferies Global Healthcare Conference

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Emeryville, California, is poised to present at the prestigious Jefferies Global Healthcare Conference in New York. The event will take place on June 4, 2025, at 4:55 PM ET, and will feature a presentation from the company’s Chief Executive Officer, Warner Biddle.

This conference serves as a vital platform for investors, analysts, and industry leaders, offering an opportunity to gain insights into the most recent developments in the healthcare sector. Kyverna, traded on Nasdaq under the ticker KYTX, aims to address the growing need for advanced treatment options for patients suffering from autoimmune diseases through innovative cell therapies.

About Kyverna Therapeutics

Founded with the mission to liberate patients through the power of cell therapy, Kyverna is at the forefront of developing CAR T-cell therapies aimed at treating a range of autoimmune conditions. Their lead candidate, KYV-101, is currently progressing through late-stage clinical trials, specifically targeting stiff person syndrome and myasthenia gravis. The company is also conducting two multi-center Phase 1/2 trials focused on lupus nephritis, demonstrating its commitment to addressing complex autoimmune disorders.

Kyverna’s strategic approach involves leveraging its extensive research to explore additional indications for its therapies. Ongoing investigations include evidence-gathering studies in multiple sclerosis, which will inform future trial efforts and enhance the company’s pipeline.

The Importance of CAR T-cell Therapy

CAR T-cell therapy represents a cutting-edge treatment paradigm, where a patient’s own T cells are genetically modified to enhance their ability to combat diseases. This technology is proving transformative, particularly in treating autoimmune diseases that have been historically challenging to manage. Kyverna’s continued investment in this domain positions it well within the biopharmaceutical landscape.

Event Accessibility

For those unable to attend the conference in person, a live webcast of Kyverna’s presentation will be accessible through the Investors section of the company’s website at Kyverna Therapeutics Investor Relations. Additionally, a replay will be available for a period of 30 days following the event, ensuring that stakeholders can stay informed about the latest updates.

Future Directions

Looking ahead, Kyverna Therapeutics is keen to expand its reach within the biopharmaceutical industry. By advancing their CAR T-cell therapies and bolstering their research on autoimmune disorders, they aim to address unmet medical needs and redefine the treatment landscape for patients. As the company continues to innovate, it holds promise not just for therapeutic advancements but also for enhancing the quality of life for those affected by debilitating conditions.

In conclusion, with unique therapeutic offerings and a strong pipeline, Kyverna Therapeutics is poised to make a considerable impact in the realm of autoimmune disease treatment. The upcoming presentation at the Jefferies Global Healthcare Conference is an excellent opportunity for the company to showcase its progress and vision for the future.